Low nirmatrelvir/ritonavir use among patients with rheumatoid arthritis: a signal of concern

Individuals with rheumatoid arthritis (RA) may be at increased risk of severe coronavirus disease 2019 (COVID-19) outcomes. Nirmatrelvir/ritonavir has been shown to reduce the risk for hospitalization and death among patients with COVID-19 at risk for progression to severe disease.

View Source

Information

Citation

Kwok TSH, Kuriya B, Eder L, Aghanya V, Gatley JM, Widdifield J. J Rheumatol. 2023; Oct 1 [Epub ahead of print].

View Source

Contributing ICES Scientists

Jessica Widdifield

Research Programs

Chronic Disease & Pharmacotherapy

Associated Topics

Associated Sites

ICES Central

Discover More

Journal Article

02/07/2025

Variations in end-of-life symptom management medication prescribing among home care recipients in Ontario, Canada

Fremont D, Downar J, Seow H, Tanuseputro P, Webber C. J Pain Symptom Manage. 2025; S0885-3924(25)00702-X. Epub 2025 Jul 2.

Journal Article

01/07/2025

Duration of methadone and buprenorphine-naloxone treatment

Kleinman RA, Kurdyak P. JAMA Netw Open. 2025; 8(7):e2518389.

Journal Article

01/07/2025

COVID-19 vaccine uptake in a retrospective population-based cohort of people living with and without HIV in Ontario, Canada

Freitas C, Cooper CL, Kroch AE, Moineddin R, Arbess G, Benoit AC, Buchan SA, Chambers C, Habanyama M, Kendall CE, Kwong JC, Mbuagbaw L, McCullagh J, Moqueet N, Nambiar D, Rueda S, Tran V, Walmsley S, Burchell AN; CHESS Study Team. Vaccine. 2025; 61:127422. Epub 2025 Jul 1.

See All